ATNM INVESTORS: Kirby McInerney LLP Reminds Actinium Pharmaceuticals, Inc. Investors of Important Deadline and Encourages Investors to Contact the Firm

Core Viewpoint - A class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. for allegedly misleading investors regarding the approval prospects of its Biologics License Application for lomab-B, leading to significant stock price decline [1][4]. Summary by Relevant Sections Class Action Lawsuit - The lawsuit is filed in the U.S. District Court for the Southern District of New York on behalf of investors who acquired Actinium securities from October 31, 2022, to August 2, 2024, with a deadline of May 27, 2025, for lead plaintiff applications [1]. Regulatory Update and Stock Performance - On August 5, 2024, Actinium announced that the FDA required an additional clinical study to support its BLA for lomab-B, resulting in a stock price drop of $3.69, or approximately 59$6.17 to $2.48 per share [3]. Allegations of Misleading Information - The complaint alleges that during the Class Period, Actinium misled the market into believing that the data submitted for its BLA would meet FDA guidelines for acceptance and approval [4].